grad-cov2
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Aug 10, 2020 (NCT04528641)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04791423 | Phase 2/Phase 3 (Phase 3) | Mar 15, 2021 | Istituto Nazionale Malattie Infettive Lazaro Spallanzani, ReiThera Srl |
| NCT04528641 | Phase 1 | Aug 10, 2020 | Istituto Nazionale Malattie Infettive Lazaro Spallanzani, ReiThera Srl |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Istituto Nazionale Malattie Infettive Lazaro Spallanzani | Academic/Hospital | 2 | 0 | 2 | 2020 |
| ReiThera Srl | For profit | 2 | 2 | 2 | 2020 |
2 organizations
Page 1 / 1